Clinical Outcomes of Ileostomy Closure during versus after Adjuvant Chemotherapy in Patients with Rectal Cancer

Table 4

Data for LARS.

	Group A	Group B	value
	(n = 92), (%)	(n = 82), (%)
LARS			0.690
No	12 (13.0%)	8 (9.8%)
Minor	38 (41.3%)	32 (40.0%)
Major	42 (45.7%)	42 (51.2%)
LARS lasting time (month; IQR)	12 (8–17)	21 (12–31)	<0.001
Seek medical advice because of LARS	25 (27.2%)	24 (29.3%)	0.759
Incontinence for flatus			0.350
Never	15 (16.3%)	16 (19.5%)
<Once a week	57 (62.0%)	42 (51.2%)
≥Once a week	20 (21.7%)	24 (29.3%)
Incontinence for liquid stools			0.251
Never	20 (21.7%)	10 (12.2%)
<Once a week	54 (58.7%)	54 (65.9%)
≥Once a week	18 (19.6%)	18 (22.0%)
Frequency of bowel movements			0.134
>7 times a day	16 (17.4%)	21 (25.6%)
4–7 times a day	45 (49.0%)	32 (39.0%)
1–3 times a day	28 (30.4%)	21 (25.6%)
<Once a day	3 (3.2%)	8 (9.8%)
Clustering of stools			0.467
Never	4 (4.3%)	1 (1.2%)
<Once a week	53 (57.6%)	49 (59.8%)
≥Once a week	35 (38.0%)	32 (39.0%)
Urgency			0.032
Never	12 (13.0%)	2 (2.4%)
<Once a week	57 (62.0%)	54 (65.9%)
≥Once a week	23 (25.0%)	26 (31.7%)

LARS, low anterior resection syndrome; IQR, interquartile range; .